Your 25-second video preview has ended.

to continue watching, please Log In or Register:

Log in / Register

SAILOR Cohort 1 Results

Dr. Boyer discusses the SAILOR cohort 1 results which evaluated safety, efficacy, and tolerability of intravitreal treatment of ranibizumab (trade name Lucentis) in patients with wet AMD.

Comments (0)